Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
暂无分享,去创建一个
I. Flinn | F. Awan | T. Phillips | D. Brander | M. Tees | S. Parikh | M. Farooqui | H. Eradat | D. Stephens | J. Woyach | N. Reddy | J. Byrd | R. Ghori